Mark Ma

Mark Ma serves as the Head of Translational Sciences and Early Development at Rallybio since March 2022, having previously held the position of Head of Translational Clinical Science. Prior to this role, Mark Ma was the Executive Director at Alexion Pharmaceuticals/AstraZeneca Rare Disease from July 2021 to March 2022 and served as Executive Director and Sr. Director of Bioanalytical Development at Alexion Pharmaceuticals, Inc. from October 2015 to August 2021. Mark Ma's earlier experience includes working as the Director of Pre-clinical at Amgen from June 2002 to September 2015.